Addex Therapeutics Ltd (ADXN)
ADXN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 20-F (ifrs-full:RevenueFromContractsWithCustomers), period ending 2024-12-31, https://www.sec.gov/Archives/edgar/data/1574232/000110465925049380/0001104659-25-049380-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), period ending 2024-12-31. Converted from CHF at 0.8334 per USD (ECB reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | ADXN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Switzerland |
| IPO year | Not reported by the screener |
| SEC CIK | 0001574232 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | V8 |
Financials · 2024
| Line | Value |
|---|---|
| Revenue | $485K |
| Net income | $8.5M |
| Operating income | Not in SEC XBRL data |
| Net margin | 1746.0% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | Not in SEC XBRL data |
| Total assets | Not in SEC XBRL data |
| P/E (computed) | 0.6× |
| P/S (computed) | 10.6× |
Reported in CHF; shown in US dollars.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-12-10 |
| Latest annual report FORM 20-F | 20-F | 2026-05-15 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-10-08 |
Source: SEC EDGAR submissions feed, 278 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| GELS | Gelteq Limited | $0.4801 | -2.06% | $5.1M |
| PULM | Pulmatrix Inc. | $1.38 | -3.50% | $5.0M |
| KALA | KALA BIO Inc. | $0.2600 | -7.14% | $5.0M |
| PCSA | Processa Pharmaceuticals Inc. | $1.77 | -6.84% | $5.0M |
| SCNX | Scienture Holdings Inc. | $3.24 | -17.14% | $5.3M |
| XBIO | Xenetic Biosciences Inc. | $2.10 | -0.94% | $4.9M |
| XTLB | XTL Biopharmaceuticals Ltd. | $1.98 | +3.12% | $4.9M |
| LNAI | Lunai Bioworks Inc. | $1.03 | -7.21% | $4.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier